Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor
(CAR) is rapidly emerging as a promising new treatment for haematological and non …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …

Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly
emerging a promising new treatment for haematological and non-haematological …

Chimeric antigen receptor (CAR) T cell therapy, together with checkpoint inhibition, has
been celebrated as a breakthrough technology due to the substantial benefit observed in …

Therapeutic ex vivo T-cell expansion is limited by low rates and T-cell products of limited
functionality. Here we describe a system that mimics natural antigen-presenting cells (APCs) …

The field of gene therapy is striving more than ever to define a path to the clinic and the
market. Twenty gene therapy products have already been approved and over two thousand …

Extracellular nanovesicles (ENV) released by many cells contain lipids, proteins, and
nucleic acids that contribute to intercellular communication. ENVs have emerged as …

Immune-based therapies have revolutionized cancer treatments. Cardiovascular sequelae
from these treatments, however, have emerged as critical complications, representing new …

Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-
cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma. However …